Conformis and Medacta reached a settlement in a patent dispute, the devicemakers said.
Under the settlement, Medacta will receive a non-exclusive license to some Conformis patents related to patient-specific instruments with knee and shoulder implants, Conformis said Nov. 14. Medacta on Nov. 15 said the settlement also "contemplates the payment of a sum in a low single digit million-dollar amount."
"Through this settlement, we have once again monetized our patient-specific instrument patents and steadfastly protected our patient-specific implant products and services," Conformis President and CEO Mark Augusti said in a statement.